PPARG and neoplasm: Variability in PPARγ-mediated effects on cell proliferation couldarise from tumor heterogeneity in nuclear receptor cross-talk, complement ofcofactors, or mutated or aberrant signaling pathways that override PPARγ signaling, leading to an apparent lack ofeffect of rosiglitazone [74–77].